OncoMatch/Clinical Trials/NCT06888063
Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery
Is NCT06888063 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Hepatic Arterial Infusion Pump chemotherapy with floxuridin for intrahepatic bile duct cancer.
Treatment: Hepatic Arterial Infusion Pump chemotherapy with floxuridin — The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery. The main questions it aims to answer are: * Does addition of chemotherapy by means of a chemo pump lead to less return of disease within the liver two years after surgery? * Does addition of chemotherapy by means of a chemo pump lead to longer survival of patients? * Does addition of chemotherapy by means of a chemo pump lead to an increase in quality of life? Participants will receive an implanted chemo pump, through which additional chemotherapy will be given to the liver in addition to surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Excluded: DPYD homozygous deficiency
Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency
Performance status
ECOG OR WHO 0–1
Prior therapy
Cannot have received: hepatic radiation
Prior hepatic radiation for iCCA
Cannot have received: ablation
Prior ablation for iCCA
Cannot have received: resection
Prior resection for iCCA
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; White blood cell count (WBC) ≥ 2.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Haemoglobin (Hb) ≥ 5.5 mmol/L; adequate bone marrow function before inclusion (values may be max. 30 days old)
Kidney function
Glomerular filtration rate (GFR) ≥ 30 ml/min; adequate renal function before inclusion (values may be max. 30 days old)
Liver function
Total bilirubin ≤ 25 µmol/L; adequate liver function before inclusion (values may be max. 30 days old)
Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old) Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L White blood cell count (WBC) ≥ 2.5 x 10^9/L Platelets ≥ 100 x 10^9/L Glomerular filtration rate (GFR) ≥ 30 ml/min Haemoglobin (Hb) ≥ 5.5 mmol/L Total bilirubin ≤ 25 µmol/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify